Froedtert & the Medical College of Wisconsin Cancer Network is First in the World to Treat Cancer Patient Using the Accuray Radixact® System with Synchrony® Motion Tracking and Correction Technology
The Froedtert &
"The Froedtert & MCW Radiation Oncology team continues to identify and integrate technical advancements that have the potential to make radiation therapy treatment as precise, safe and effective as possible," said
"In our hospital network we've seen an increase in the use of hypofractionated stereotactic body radiation therapy as part of the cancer treatment, making it critically important that we are able to safely deliver the correct amount of dose precisely to the tumor, even to those that move such as tumors in thorax, abdomen and pelvis," said
Listen to the Froedtert & MCW Radiation Oncology team share their experiences using Radixact with Synchrony at this link: https://youtu.be/SRIbJ3_MeKs
Synchrony for the Radixact System is designed to correct for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement. Synchrony is the only technology that uses image guidance during treatment delivery to automatically adjust the movement of the radiation beam in synchronization with the movement of the tumor. The beams of radiation are delivered continuously throughout the treatment session as the patient breathes naturally. In comparison, gating methods deliver radiation only when the tumor is close to the expected location and pause treatment delivery when the moving tumor is outside of the "treatment window." This potentially lengthens the treatment time and can compromise clinical efficacy.
Additionally, the combination of Synchrony® with the Radixact® System facilitates the efficient and effective delivery of both hypofractionated and standard radiation therapy, making it easier for clinical teams to provide treatments tailored to meet each individual patient's needs. This functionality directly supports the key priority of value-based healthcare delivery models, such as an Alternative Payment Model, which economically reward treatment quality and efficiency to improve patient outcomes. The combination of Synchrony® with the Radixact® System is a big step forward for patients, and clinical providers who treat them.
"We congratulate Dr. Schultz, Dr. Li and the entire Froedtert & MCW Cancer Network team on treating the first cancer patient using the Radixact System with Synchrony," said
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and the ability of Synchrony to expand the treatment options for patients with mobile tumors as well as the range of tumors being treated with the Radixact® System. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings and improvements; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products, including product improvements, for certain users and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director,
+1 (408) 789-4426
+1 (781) 684-6610
1 "Synchrony® Motion Tracking and Correction Technology" is synonymous with the development name: "Motion Tracking and Compensation Feature for the Radixact® Treatment Delivery System"
View original content to download multimedia:http://www.prnewswire.com/news-releases/froedtert--the-medical-college-of-wisconsin-cancer-network-is-first-in-the-world-to-treat-cancer-patient-using-the-accuray-radixact-system-with-synchrony-motion-tracking-and-correction-technology-300904807.html